Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 9/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808747 | 1.00 | HTR2A (0.55) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL20997590 | 1.00 | HTR2A (0.55) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL13192766 | 1.00 | HTR2A (0.55) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL20202734 | 1.00 | HTR2A (0.55) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL8329699 | 0.82 | KDM1A (0.41) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL14141377 | 0.80 | GRIA4 (0.51) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL31412689 | 0.79 | KDM1A (0.44) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL23995537 | 0.79 | KDM1A (0.70) | HTR2AHTR2CHTR2BKDM1AKCNH2 | |
| SCHEMBL23993641 | 0.79 | KDM1A (0.51) | HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL19444133 | 0.79 | KDM1A (0.70) | HTR2AHTR2CHTR2BKDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109775-A1 | PYRIMIDINE-ANNULATED TRIAZOLE DERIVATIVES AND THEIR USE IN PLATELET AGGREGATION INHIBITION | BEIJING HONGHUI MEDITECH CO., LTD (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-9604991-B2 | Preparation method of ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-28 | — | — | US | disclosed |
| US-7863469-B2 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | TBXA2R, F2R, F2 | HTR2A 372/4885HTR2C 474/4885HTR2B 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.